NCT04082364 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04082364
Title	Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)
Acronym	MAHOGANY
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	MacroGenics
Indications	gastroesophageal junction adenocarcinoma stomach cancer
Therapies	Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab Capecitabine + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Margetuximab-cmkb + Retifanlimab Capecitabine + Margetuximab-cmkb + MGD013 + Oxaliplatin Capecitabine + Oxaliplatin + Trastuzumab Fluorouracil + Leucovorin + Margetuximab-cmkb + Oxaliplatin + Retifanlimab Capecitabine + Margetuximab-cmkb + Oxaliplatin Fluorouracil + Leucovorin + Margetuximab-cmkb + MGD013 + Oxaliplatin
Age Groups:	senior \| adult
Covered Countries	USA \| POL \| ITA \| GBR \| DEU

Additional content available in CKB BOOST